Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02,...
-
Rare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level 1 randomized controlled trialPositions MagnetOs above most other...
-
MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020Kuros expanding MagnetOs range to increase perioperative solutions for surgeons SCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE...
-
New products expand perioperative solutions for surgeonsData to be presented on new formulation of MagnetOs that includes a collagen carrier SCHLIEREN (ZURICH), Switzerland, Sept. 28, 2021 (GLOBE...
-
SCHLIEREN (ZURICH), Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has...
-
Financial highlights CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020Revenues increased by 58% to CHF 4.0 million Operational highlights Initiated...
-
New data on the role of osteoimmunology in bone formation at BritSpine MeetingInvestor presentation at BioCapital Europe SCHLIEREN (ZURICH), Switzerland, March 10, 2021 (GLOBE NEWSWIRE) -- Kuros...
-
Agreements in Netherlands, Switzerland and Austria and letter of intent in FinlandSupports further acceleration of sales of MagnetOs bone graft SCHLIEREN (ZURICH), Switzerland, March 02, 2021 ...
-
SCHLIEREN (ZURICH), Switzerland, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kuros Biosciences corrects gross proceeds raised in first bullet point and second paragraph to $75 million from $86.25 million....
-
Total gross proceeds raised by Checkmate in IPO of $86.25 million (including sale of overallotment shares)Intention to use part of the net proceeds from the IPO to fund the development of its product...